Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2019 | Nov. 13, 2019 | |
Document And Entity Information | ||
Entity Registrant Name | Microbot Medical Inc. | |
Entity Central Index Key | 0000883975 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2019 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business Flag | true | |
Entity Emerging Growth Company | false | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 4,307,666 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2019 |
Interim Consolidated Balance Sh
Interim Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 | |
Current assets: | |||
Cash and cash equivalents | $ 3,548 | $ 5,238 | |
Short term investment | 2,503 | ||
Restricted cash | 4,250 | 25 | |
Prepaid expenses and other assets | 186 | 568 | |
Total current assets | 10,487 | 5,831 | |
Property and equipment, net | 215 | 259 | |
Operating right-of-use assets | 421 | ||
Total assets | 11,123 | 6,090 | |
Current liabilities: | |||
Accounts payables | 282 | 630 | |
Provision for extinguishment dispute | 3,553 | 3,375 | |
Lease liabilities | 314 | ||
Accrued liabilities | 440 | 755 | |
Total current liabilities | 4,589 | 4,760 | |
Non current liabilities: | |||
Long-term lease liabilities | 131 | ||
Total liabilities | 4,720 | 4,760 | |
Commitments and contingencies | |||
Stockholders' equity: | |||
Common stock; $0.01 par value; 60,000,000 shares authorized as of September 30, 2019 and December 31, 2018 4,307,666 and 3,012,343 shares issued and outstanding as of September 30, 2019 and December 31, 2018 | 43 | 31 | |
Additional paid-in capital | [1] | 42,976 | 32,538 |
Treasury shares | (3,375) | (3,375) | |
Accumulated deficit | (33,241) | (27,864) | |
Total stockholders' equity | 6,403 | 1,330 | |
Total liabilities and stockholders' equity | $ 11,123 | $ 6,090 | |
[1] | The Company adopted ASU 2017-11 using the full retrospective approach. Refer to Note 6 for further information. |
Interim Consolidated Balance _2
Interim Consolidated Balance Sheets (Parenthetical) - $ / shares | Sep. 30, 2019 | Sep. 10, 2019 | Dec. 31, 2018 |
Statement of Financial Position [Abstract] | |||
Common stock, par value | $ 0.01 | $ 0.01 | |
Common stock, shares authorized | 60,000,000 | 220,000,000 | 60,000,000 |
Common stock, shares issued | 4,307,666 | 3,012,343 | |
Common stock, shares outstanding | 4,307,666 | 3,012,343 |
Interim Consolidated Statements
Interim Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||
Sep. 30, 2019 | Sep. 30, 2018 | [1] | Sep. 30, 2019 | Sep. 30, 2018 | [1] | |
Income Statement [Abstract] | ||||||
Research and development | $ 843 | $ 623 | $ 2,207 | $ 1,866 | ||
General and administrative | 948 | 1,130 | 3,045 | 3,294 | ||
Operating loss | (1,791) | (1,753) | (5,252) | (5,160) | ||
Financing income (expenses), net | (83) | (5) | (125) | 26 | ||
Net loss | $ (1,874) | $ (1,758) | $ (5,377) | $ (5,134) | ||
Basic and diluted net loss per share | $ (0.44) | $ (0.60) | $ (1.27) | $ (1.79) | ||
Basic and diluted weighted average common shares outstanding | 4,307,666 | 2,947,633 | 4,234,663 | 2,876,020 | ||
[1] | Reclassified |
Interim Consolidated Statemen_2
Interim Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | ||||
Statement of Comprehensive Income [Abstract] | |||||||
Net loss | $ (1,874) | $ (1,758) | [1] | $ (5,377) | $ (5,134) | [1] | |
Other comprehensive loss (income): | |||||||
Net unrealized loss (gain) on available for sale securities | [2] | ||||||
Comprehensive loss | $ (1,874) | $ (1,758) | $ (5,377) | $ (5,134) | |||
[1] | Reclassified | ||||||
[2] | Represents amount less than 1 thousand. |
Interim Consolidated Statemen_3
Interim Consolidated Statements of Shareholder's Equity - USD ($) $ in Thousands | Series A Preferred Shares [Member] | Common Stock [Member] | Additional Paid-In Capital [Member] | Treasury Shares [Member] | [4] | Accumulated Other Comprehensive Loss [Member] | Accumulated Deficit [Member] | [3] | Total | Temporary Equity [Member] | [5] | ||||
Balance at Dec. 31, 2017 | [1] | $ 27 | [2] | $ 30,569 | [3] | $ (20,604) | $ 9,992 | $ 500 | |||||||
Balance, shares at Dec. 31, 2017 | 4,001 | 2,734,300 | [2] | ||||||||||||
Share-based compensation | [2] | 1,139 | [3] | 1,139 | |||||||||||
Exercise of options | [1],[2] | [3] | |||||||||||||
Exercise of options, shares | 2,487 | [2] | |||||||||||||
Shares issued as consideration-vendors | $ 1 | [2] | 73 | [3] | 74 | ||||||||||
Shares issued as consideration-vendors, shares | 6,738 | [2] | |||||||||||||
Conversion of preferred A shares to common stock | $ 2 | [2] | (2) | [3] | |||||||||||
Conversion of preferred A shares to common stock, shares | (3,451) | 232,152 | [2] | ||||||||||||
Net loss | [2] | [3] | (5,134) | (5,134) | [6] | ||||||||||
Balance at Sep. 30, 2018 | [1] | $ 30 | [2] | 31,779 | [3] | (25,738) | 6,071 | 500 | |||||||
Balance, shares at Sep. 30, 2018 | 550 | 2,975,677 | [2] | ||||||||||||
Balance at Dec. 31, 2017 | [1] | $ 27 | [2] | 30,569 | [3] | (20,604) | $ 9,992 | 500 | |||||||
Balance, shares at Dec. 31, 2017 | 4,001 | 2,734,300 | [2] | ||||||||||||
Exercise of options, shares | 2,487 | ||||||||||||||
Balance at Dec. 31, 2018 | [1] | $ 31 | [2] | 32,538 | [3] | (3,375) | (27,864) | $ 1,330 | |||||||
Balance, shares at Dec. 31, 2018 | 3,012,343 | [2] | |||||||||||||
Balance at Jun. 30, 2018 | [1] | $ 30 | 31,462 | (23,980) | 7,512 | 500 | |||||||||
Balance, shares at Jun. 30, 2018 | 1,001 | 2,945,677 | |||||||||||||
Share-based compensation | [2] | 317 | [3] | 317 | |||||||||||
Exercise of options | [2] | [3] | |||||||||||||
Exercise of options, shares | |||||||||||||||
Conversion of preferred A shares to common stock | [2] | [3] | |||||||||||||
Conversion of preferred A shares to common stock, shares | (451) | 30,000 | [2] | ||||||||||||
Net loss | [2] | [3] | (1,758) | (1,758) | [6] | ||||||||||
Balance at Sep. 30, 2018 | [1] | $ 30 | [2] | 31,779 | [3] | (25,738) | 6,071 | 500 | |||||||
Balance, shares at Sep. 30, 2018 | 550 | 2,975,677 | [2] | ||||||||||||
Balance at Dec. 31, 2018 | [1] | $ 31 | [2] | 32,538 | [3] | (3,375) | (27,864) | 1,330 | |||||||
Balance, shares at Dec. 31, 2018 | 3,012,343 | [2] | |||||||||||||
Share-based compensation | [2] | 906 | [3] | 906 | |||||||||||
Issuance of common stock and warrants net of issuance expenses | $ 12 | [2] | 9,532 | [3] | 9,544 | ||||||||||
Issuance of common stock and warrants net of issuance expenses, shares | 1,295,323 | [2] | |||||||||||||
Unrealized loss on marketable debt security | [2] | [3] | |||||||||||||
Net loss | [2] | [3] | (5,377) | (5,377) | |||||||||||
Balance at Sep. 30, 2019 | [1] | $ 43 | [2] | 42,976 | [3] | (3,375) | (33,241) | 6,403 | |||||||
Balance, shares at Sep. 30, 2019 | 4,307,666 | [2] | |||||||||||||
Balance at Jun. 30, 2019 | [1] | $ 43 | [2] | 42,680 | [3] | (3,375) | (31,367) | 7,981 | |||||||
Balance, shares at Jun. 30, 2019 | 4,307,666 | [2] | |||||||||||||
Share-based compensation | [2] | 296 | [3] | 296 | |||||||||||
Issuance of common stock and warrants net of issuance expenses | [2] | [3] | |||||||||||||
Issuance of common stock and warrants net of issuance expenses, shares | [2] | ||||||||||||||
Unrealized loss on marketable debt security | [2] | [3] | |||||||||||||
Net loss | [2] | [3] | (1,874) | (1,874) | |||||||||||
Balance at Sep. 30, 2019 | [1] | $ 43 | [2] | $ 42,976 | [3] | $ (3,375) | $ (33,241) | $ 6,403 | |||||||
Balance, shares at Sep. 30, 2019 | 4,307,666 | [2] | |||||||||||||
[1] | Less than 1 | ||||||||||||||
[2] | Share data as of December 31, 2017, June 30, 2018, and for the periods then ended represent the number of shares adjusted to retroactively reflect the 1:15 reverse stock split effected on September 4, 2018. Refer to Note 1 for further information. | ||||||||||||||
[3] | Refer to Note 5 for further information | ||||||||||||||
[4] | Refer to Note 4 for further information | ||||||||||||||
[5] | Includes 721,107 common stock classified as temporary equity as of December 31, 2017. | ||||||||||||||
[6] | Reclassified |
Interim Consolidated Statemen_4
Interim Consolidated Statements of Shareholder's Equity (Parenthetical) | Dec. 31, 2017shares |
Statement of Stockholders' Equity [Abstract] | |
Temporary equity | 721,107 |
Interim Consolidated Statemen_5
Interim Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | ||
Operating activities: | |||
Net loss | $ (5,377) | $ (5,134) | [1] |
Adjustments to reconcile net loss to net cash flows from operating activities: | |||
Depreciation and amortization | 44 | 49 | |
Share-based compensation expense | 906 | 1,139 | |
Shares issued to a vendor | 74 | ||
Amortization of discount (premium) on marketable debt securities | (7) | ||
Changes in assets and liabilities: | |||
Accounts receivable | 364 | (32) | |
Other payables and accrued liabilities | (461) | 29 | |
Net cash flows from operating activities | (4,531) | (3,875) | |
Investing activities: | |||
Purchase of property and equipment | (239) | ||
Purchase of marketable debt securities | (2,496) | ||
Net cash flows from investing activities | (2,496) | (239) | |
Financing activities: | |||
Issuance of common stock and warrants, net of issuance costs | 9,562 | ||
Net cash flows from financing activities | 9,562 | ||
Increse (decrease) in cash, cash equivalents and restricted cash | 2,535 | (4,114) | |
Cash, cash equivalents and restricted cash at beginning of period | 5,263 | 10,814 | |
Cash, cash equivalents and restricted cash at ending of period | 7,798 | 6,700 | |
Non-cash investing and financing activities: | |||
Recognition of right-of-use asset and lease liability upon adoption of ASU 2016-02 | 630 | ||
Supplemental disclosure of cash flow information: | |||
Cash received from interest | $ 61 | ||
[1] | Reclassified |
General
General | 9 Months Ended |
Sep. 30, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
General | NOTE 1 - GENERAL A. Description of Business: Microbot Medical Inc. (the “Company”) is a pre-clinical medical device company specializing in the research, design and development of next generation micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of improving surgical outcomes for patients. It was incorporated on August 2, 1988 in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate of Incorporation was restated on February 14, 1992 to change the name of the Company to Cyto Therapeutics, Inc. On May 24, 2000, the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc. On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel”). On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “MBOT”. Prior to the Merger, the Company was a biopharmaceutical company that conducted research, development, and commercialization of stem cell therapeutics and related technologies. The sale of substantially all material assets relating to the stem cell business were completed on November 29, 2016. The Company and its subsidiaries are collectively referred to as the “Company”. “StemCells” or “StemCells, Inc.” refers to the Company prior to the Merger. B. Going Concern: The unaudited financial statements as of September 30, 2019 have been prepared under the assumption that the Company will continue as a going concern for the next 12 months. The Company’s ability to continue as a going concern is dependent upon its uncertain ability to obtain additional equity and/or debt financing and reduce expenditures. The Company has incurred operating losses and negative cash flows from operating activities each year since inception. As of September 30, 2019, the Company had an accumulated deficit of approximately $33,241. Due to continuing research and development activities, the Company expects to continue to incur additional losses for the foreseeable future. The Company’s management plans to continue to fund its current operations as well as other development activities relating to additional product candidates, through future issuances of either debt and/or equity securities and possibly additional grants from the Israeli Innovation Authority and other government institutions. The Company’s ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. These factors raise substantial doubt to the company’s ability to continue as a going concern. The accompanying financial statements as of September 30, 2019 do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on the financial statements. C. Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates. D. Reverse Stock Split: On September 4, 2018, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to affect a one-for-15 reverse stock split of the Company’s common stock (the “Reverse Split”). As a result of the Reverse Split, every 15 shares of the Company’s old common stock were converted into one share of the Company’s new common stock. Fractional shares resulting from the Reverse Split were rounded up to the nearest whole number. The Reverse Split automatically and proportionately adjusted, based on the one-for-fifteen split ratio, all issued and outstanding shares of the Company’s common stock, as well as common stock underlying convertible preferred stock, stock options, warrants and other derivative securities outstanding at the time of the effectiveness of the Reverse Split. The exercise price on outstanding equity based-grants was proportionately increased, while the number of shares available under the Company’s equity-based plans was also proportionately reduced. Share and per share data (except par value) for the periods presented reflect the effects of the Reverse Split. References to numbers of shares of common stock and per share data in the accompanying financial statements and notes thereto for periods ended prior to September 4, 2018 have been adjusted to reflect the Reverse Split on a retroactive basis. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2019 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Unaudited Interim Financial Statements: The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission (“SEC”) regulations. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). Operating results for the three- and nine-month periods ended September 30, 2019, are not necessarily indicative of the results that may be expected for the year ended December 31, 2019. Significant Accounting Policies: The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual audited financial statements with the exception of the following: Short-term Investments: The Company began investing excess cash in short-term investments during the first quarter of 2019. Marketable debt securities are considered to be available for sale and are carried at fair value. Unrealized gains and losses net of tax, if any, are reported as a separate component of shareholders’ equity. The cost of marketable debt securities classified as available for sale is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Realized gains and losses and declines in value judged to be other than temporary, if any, are also included in other income, net. Interest on securities classified as available for sale is included in interest income. The cost of securities sold is based on the specific identification method. Management evaluates whether available-for-sale securities are other-than-temporarily impaired (OTTI) on a quarterly basis. Debt securities with unrealized losses are considered OTTI if the Company intends to sell the security or if it is more likely than not that the Company will be required to sell such security prior to any anticipated recovery. If management determines that a security is OTTI under these circumstances, the impairment recognized in earnings is measured as the entire difference between the amortized cost and the then-current fair value. During the three and nine-months ended September 30, 2019, no investment OTTI losses were realized. Fair Value of Financial Instruments: The carrying values of cash and cash equivalents, other receivable and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. The Company measures the fair value of certain of its financial instruments (marketable debt security) on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 Level 2 Level 3 Reclassifications: Leases: In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842). This ASU requires entities that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than 12 months. The Company adopted this ASU effective January 1, 2019 using the modified retrospective application, applying the new standard to leases in place as of the adoption date. Prior periods have not been adjusted. Arrangements that are determined to be leases at inception are recognized as long-term right-of-use assets (“ROU”) and lease liabilities in the condensed consolidated balance sheet at lease commencement. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future fixed lease payments over the lease term at commencement date. As most of the Company’s leases do not provide an implicit rate, the Company applies its incremental borrowing rate based on the economic environment at commencement date in determining the present value of future payments. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases or payments are recognized on a straight-line basis over the lease term. Warrants: Prior to January 1, 2019, warrants with non-standard anti-dilution provisions (referred to as down round protection) were classified as liabilities and re-measured each reporting period. On January 1, 2019, the Company adopted the provisions of Accounting Standards Update (“ASU”) 2017-11, which includes Part I “Accounting for Certain Financial Instruments with Down Round Features” and Part II “Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-Controlling Interests with a Scope Exception”, which indicates that a down round feature no longer precludes equity classification when assessing whether an investment is indexed to an entity’s own stock. The Company used a full retrospective approach to adoption and restated its financial statements as of the earliest period presented. As a result of the adoption of ASU 2017-11, the Company’s warrants were reclassified from liabilities to shareholders’ equity. The cumulative effect of adoption of ASU 2017-11 resulted as follows: For the For the Derivative warrant liability $ (5 ) $ (8) Additional paid-in capital $ 3 $ 28 Accumulated deficit $ 2 $ 20 Refer to Note 6 for further information regarding the outstanding warrants as of September 30, 2019. Recent Accounting Standards: In June 2016, the FASB issued ASU 2016-13 “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. This ASU replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. This ASU is effective for the Company in the first quarter of 2020, with early adoption permitted. The Company does not expect that this ASU will have a material effect on the Company’s consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements”, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. This ASU removes, modifies, and adds certain disclosure requirements, and is effective for the Company beginning on January 1, 2020. The Company does not expect that this ASU will have a material effect on the Company’s consolidated financial statements. |
Short-Term Investments
Short-Term Investments | 9 Months Ended |
Sep. 30, 2019 | |
Short-term Investments [Abstract] | |
Short-Term Investments | NOTE 3 - SHORT-TERM INVESTMENTS The following table summarizes the Company’s marketable debt securities as of September 30, 2019 and December 31, 2018. As of September 30, 2019 Amortized cost Unrealized gains Realized gains Fair value US Treasury Bond $ 2,503 $ - $ - $ 2,503 As of December 31, 2018 Amortized Cost Unrealized gains Realized gains Fair value US Treasury Bond $ - $ - $ - $ - The Company’s financial asset is measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s marketable security is classified as Level 1. Other than the marketable debt security, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value. The contractual maturity of the marketable security is one year. |
Leases
Leases | 9 Months Ended |
Sep. 30, 2019 | |
Leases [Abstract] | |
Leases | NOTE 4 - LEASES On January 1, 2019, the Company adopted ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”) using the modified retrospective approach for all lease arrangements at the beginning period of adoption. Leases existing for the reporting period beginning January 1, 2019 are presented under ASU 2016-02. The Company leases office space and vehicles under operating leases. At September 30, 2019, the Company’s ROU assets and lease liabilities for operating leases totaled $421 and $445, respectively. The impact of adopting the new lease standard was not material to the Company’s condensed consolidated statement of operations for the periods presented. Supplemental cash flow information related to operating leases was as follows (unaudited): Nine Months ended September 30, 2019 Cash payments for operating leases $ 235 Leases recorded on the balance sheet consist of the following (in thousands): September 30, 2019 Assets Operating lease right of use asset $ 421 Liabilities Operating lease – current $ 314 Operating lease - non-current $ 131 $ 445 September 30, 2019 Operating leases weighted average remaining lease term (in years) 2 Operating leases weighted average discount rate 7 % Undiscounted maturities of operating lease payments as of September 30, 2019 are summarized as follows (in thousands): Operating Leases Remainder of 2019 $ 83 2020 302 2021 79 Total future lease payments $ 464 Less imputed interest (19 ) Total lease liability balance $ 445 |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | NOTE 5 - COMMITMENTS AND CONTINGENCIES Government Grants: Microbot Israel obtained from the Israeli Innovation Authority (“IIA”) grants for participation in research and development for the years 2013 through September 30, 2019 in the total amount of approximately $1,500 and, in return, Microbot Israel is obligated to pay royalties amounting to 3%-3.5% of its future sales up to the amount of the grant. The grant is linked to the exchange rate of the dollar to the New Israeli Shekel and bears interest of Libor per annum. The repayment of the grants is contingent upon the successful completion of the Company’s research and development programs and generating sales. The Company has no obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial risk is assumed completely by the Government of Israel. The grants are received from the Government on a project-by-project basis. TRDF Agreement: Microbot Israel signed an agreement with the Technion Research and Development Foundation (“TRDF”) in June 2012 by which TRDF transferred to Microbot Israel a global, exclusive, royalty-bearing license. As partial consideration for the license, Microbot Israel shall pay TRDF royalties on net sales (between 1.5%-3%) and on sublicense income as detailed in the agreement. Contract Research Agreements: Agreement with Washington University On January 27, 2017, the Company entered into a Contract Research Agreement (the “Research Agreement”) with The Washington University (“Washington U.”), pursuant to which the parties are collaborating to determine the effectiveness of the Company’s self-cleaning shunt. The study in Washington U. includes several phases. The first phase (initial research) was completed. An agreement on the second phase was entered in September 2018 with total expected costs of approximately $248. As of September 30, 2019, his study is still on going and will be extended to continue until March 1, 2020. Pursuant to the Research Agreement, all rights, title and interest in the data, information and results obtained or arrived at by Washington U. in the performance of its services under the Research Agreement, as well as any patentable inventions obtained or arrived at in the performance of such services, will be jointly owned by the Company and Washington U., and each will have full right to practice and grant licenses in joint inventions. Additionally, Washington U. granted to the Company: (a) a non-exclusive, worldwide, royalty-free, fully paid-up, perpetual and irrevocable license to use and practice patentable inventions (other than joint inventions and improvements to Washington U.’s animal models) obtained or arrived at by Washington U. in the provision of its services under the Research Agreement (“University Inventions”) with respect to the self-cleaning shunt; and (b) an exclusive option to obtain an exclusive worldwide license in University Inventions, on terms to be negotiated between the parties. Agreement with Wayne State University On September 12, 2016, the Company entered into a research agreement (the “WSU Agreement”) with Wayne State University (“WSU.”), pursuant to which the parties are collaborating to determine the efficacy of the Company’s self-cleaning shunt. The study in WSU includes several phases. The first phase (initial research) was completed. An agreement on the second phase was entered in April 2018 with total expected costs of approximately $130. In July 2018 the contract was updated to include phase 2.1 (preliminary phase to phase 2) with total expected costs of approximately $213. Pursuant to the WSU Agreement, WSU shall own all data generated by the research and the Company shall have unrestricted free right to use and disclose all the results, information and material generated from the WSU Agreement. Rights to inventions, improvements or discoveries, whether or not patentable or copyrightable made solely by the employees of the Company in the course of performance of the workplan agreed upon between the Company and WSU shall belong to the Company. Rights to inventions, improvements or discoveries, whether or not patentable or copyrightable made solely by the employees of WSU in the course of performance of the workplan agreed upon between the Company and WSU shall belong to WSU. WSU shall grant the Company with a worldwide non-exclusive, perpetual, royalty-free license to university inventions to use and practice patentable inventions. Rights to inventions, improvements or discoveries, whether or not patentable or copyrightable made by at least one employee of WSU and one employee of the Company in the course of performance of the workplan agreed upon between the Company and WSU shall belong to WSU and the Company jointly. Both the Company and WSU will be free to use and license to others the rights of joint inventions for any and all purposes without consultation or obligation to the other party. WSU granted the Company a first option to negotiate an exclusive license to use and practice WSU inventions and its interest in the joint inventions as detailed in the WSU Agreement. Sabby Litigation: The Company is named as the defendant in a lawsuit (the “Matter”), captioned Sabby Healthcare Master Fund Ltd. and Sabby Volatility Warrant Master Fund Ltd., Plaintiffs, against Microbot Medical Inc., Defendant, in the Supreme Court of the State of New York, County of New York (the “Court”) (Index No. 654581/2017). The complaint alleged, among other things, that the Company breached multiple representations and warranties contained in the Securities Purchase Agreement (the “SPA”) related to the Company’s June 8, 2017 equity financing (the “Financing”) of which the Plaintiffs participated. The complaint sought rescission of the SPA and return of the Plaintiffs’ $3,375 purchase price with respect to the Financing, and damages in an amount to be determined at trial, but alleged to exceed $1 million. A trial was held on February 11, 2019. On February 28, 2019, the Court issued a Decision and Order After Trial to rescind the SPA. The rescission would require the Plaintiffs to transfer back to the Company the shares they purchased in the Financing, and for the Company to return to Plaintiffs their purchase price of $3,375. Accordingly, the Company recorded a provision for extinguishment dispute as of $3,375 in current liabilities against Treasury shares classified in Equity. On March 27, 2019, the Company filed a Notice of Appeal and an Undertaking to stay execution of the judgment pending appeal. In accordance with New York law, in order to move forward with the appeal and to stay the lower court’s judgment, the Company placed approximately $4,200 in escrow with a surety bonding agent on March 26, 2019 in accordance with provisions set forth in the judgment from the Matter, which represents the judgment amount, plus interest and the fee to the bonding company. Accordingly, the Company recorded additional expenses of $178 with respect to interest from the judgement date and up until September 30, 2019. Tolling and Standstill Agreement: On April 4, 2018, Microbot entered into a Tolling and Standstill Agreement with Empery Asset Master, Ltd., Empery Tax Efficient LP, Empery Tax Efficient II LP, and Hudson Bay Master Fund, Ltd., the other investors in the Financing (“Other Investors”). Pursuant to the Tolling Agreement, among other things, (a) the Other Investors agree not to bring any claims against Microbot arising out of the Matter, (b) the parties agree that if Microbot reaches an agreement to settle the claims asserted by the Sabby Funds in the above suit, Microbot will provide the same settlement terms on a pro rata basis to the Other Investors, and the Other Investors will either accept same or waive all of their claims and (c) the parties froze in time the rights and privileges of each party as of the effective date of the Tolling Agreement, until (i) an agreement to settle the suit is executed; (ii) a judgment in the suit is obtained; or (iii) the suit is otherwise dismissed with prejudice. No provision has been recorded with respect to the Tolling Agreement since no settlement was reached with respect to the Matter. Alliance Litigation: On April 28, 2019, the Company brought an action against Alliance Investment Management, Ltd. (“Alliance”) in the Southern District of New York under Section 16(b) of the Securities Exchange Act of 1934, 15 U.S.C. 78p(b), to compel Alliance to disgorge short swing profits realized by Alliance from purchases and sales of the Company’s securities within a period of less than six months, while Alliance was a beneficial owner of more than 10% of the Company’s outstanding common stock and a statutory “insider” for purposes of the statute. The case is Microbot Medical Inc. v. Alliance Investment Management, Ltd., No. 19-cv-3782-GBD (SDNY). The amount of profits the Company is seeking to divest is estimated to be approximately $480,000. On August 21, 2019, Alliance filed an answer to the Company’s action claiming that Alliance’s client Joseph Mona was the “beneficial owner” of the shares traded by Alliance. On October 18, 21, and 28, Joseph Mona filed Section 16(a) and Schedule 13G reports, which are substantially similar to the reports previously filed by Alliance. On October 28, 2019, Alliance filed a motion for summary judgment requesting that the Court dismiss the claims against Alliance in view of Joseph Mona’s SEC filings. On November 7, 2019, U.S. Magistrate Judge Robert W. Lehrburger ordered Alliance to produce relevant trading records, to enable the Company to determine whether to proceed against Alliance and/or Joseph Mona. Alliance has agreed to postpone the Company’s response to their motion for summary judgment pending Alliance’s required production of the trading records. Agreement with CardioSert Ltd.: On January 4, 2018, Microbot Israel entered into an agreement with CardioSert Ltd. (“CardioSert”) to acquire certain patent-protected technology owned by CardioSert (the “Technology”). Pursuant to the Agreement, Microbot Israel made an initial payment of $50 to CardioSert and had 90-days to elect to complete the acquisition. At the end of the 90-day period, at Microbot Israel’s sole option, CardioSert shall assign and transfer the Technology to Microbot Israel and Microbot Israel shall pay to CardioSert additional amounts and securities as determined in the agreement. On April 10, 2018, Microbot delivered an Exercise Notice to CardioSert Ltd., notifying it that Microbot elected to exercise the option to acquire the Technology owned by CardioSert and therefore made an additional cash payment of $250 and 6,738 shares of common stock (100,000 shares of common stock before the Reverse Split) estimated at $74. The agreement may be terminated by Microbot Israel at any time for convenience upon 90-days’ notice. The agreement may be terminated by CardioSert in case the first commercial sale does not occur by the third anniversary of the date of signing of the agreement except if Microbot Israel has invested more than $2,000 in certain development stages, or the first commercial sale does not occur within 50 months. In each of the above termination events, or in case of breach by Microbot Israel, CardioSert shall have the right to buy back the Technology from Microbot Israel for $1.00, upon 60 days prior written notice, but only 1 year after such termination. Additionally, the agreement may be terminated by either party upon breach of the other (subject to cure). CardioSert agreed to assist Microbot Israel in the development of the Technology for a minimum of one year, for a monthly consultation fee of NIS 40,000 covering up to 60 consulting hours per month. Yehezkel (Hezi) Himelfarb Resignation: Effective as of February 1, 2019, Yehezkel (Hezi) Himelfarb, a member of the Board of Directors of the Company, and the Company’s Chief Operating Officer, resigned from all positions with the Company. Effective as of February 1, 2019, Mr. Himelfarb also resigned from his position as General Manager of Microbot Medical Ltd., a wholly owned subsidiary of the Company. As a result of Mr. Himelfarb providing certain post-resignation transition services to the Company until July 31, 2019, Mr. Himelfarb was paid his full salary and certain benefits through that date. |
Share Capital
Share Capital | 9 Months Ended |
Sep. 30, 2019 | |
Equity [Abstract] | |
Share Capital | NOTE 6 - SHARE CAPITAL Share Capital Developments: On September 10, 2019, the Company reduced its authorized number of shares of capital stock from 221,000,000 to 61,000,000, including a reduction in the number of authorized shares of common stock of the Company from 220,000,000 to 60,000,000. As of September 30, 2019, the Company had 4,307,666 shares of common stock issued and outstanding. On December 27, 2016, the Company exchanged 655,962 shares (9,735,925 shares before the Reverse Split) or rights to acquire shares of its common stock, for 9,736 shares of a newly designated class of Series A Convertible Preferred Stock. On January 5, 2017, the Company entered into a definitive securities purchase agreement with an institutional investor (the “Purchaser”) for the purchase and sale of an aggregate of 47,163 shares (700,000 shares before the Reverse Split) of common stock in a registered direct offering for $74.00 per share ($5.00 per share before the Reverse Split) or gross proceeds of $3,500. The Company paid the placement agent a fee of $210 plus reimbursement of out-of-pocket expenses, as well as other offering-related expenses. On June 5, 2017, the Company entered into a Securities Purchase Agreement with certain institutional investors (the “Investors”) providing for the issuance and sale by the Company to the Investors of an aggregate of 252,652 shares (3,750,000 shares before the Reverse Split) of common stock, at a purchase price per share of $40.50 ($2.70 before the Reverse Split). The gross proceeds to the Company was $10,125 before deducting placement agent fees and offering expenses of $922. See Note 4 – “Commitments and Contingencies-Litigation” with respect to certain rescission rights awarded to two affiliated Investors. On January 14, 2019, the Company entered into a Securities Purchase Agreement with an accredited institutional investor providing for the issuance and sale by the Company to the purchaser of an aggregate of (i) 330,000 shares of the Company’s common stock, at a purchase price per share of $6.50 and (ii) 125,323 pre-funded warrants each to purchase one share of common stock, at a purchase price per Pre-Funded Warrant of $6.49. The gross proceeds to the Company were approximately $3,000. The closing of the offering took place on January 15, 2019. The pre-funded warrants were exercised in full in January 2019. On January 15, 2019, the Company entered into a Securities Purchase Agreement with certain accredited institutional investors providing for the issuance and sale by the Company to the purchasers of an aggregate of 590,000 shares of the Company’s common stock, at a purchase price per share of $10.00. The gross proceeds to the Company were approximately $5,900. The closing of the offering took place on January 17, 2019. On January 23, 2019 the Company entered into a Securities Purchase Agreement with accredited institutional investors providing for the issuance and sale by the Company to the purchasers of an aggregate of 250,000 shares of the Company’s common stock, at a purchase price per share of $9.875. The gross proceeds to the Company were approximately $2,470. The closing of the offering took place on January 25, 2019. Employee Stock Option Grant: In September 2014, Microbot Israel’s board of directors approved a grant of 26,906 stock options (403,592 stock options before the Reverse Split) (77,846 stock options as retroactively adjusted to reflect the Merger) to its CEO, through MEDX Venture Group LLC. Each option was exercisable into an ordinary share, at an exercise price of $12.00 ($0.80 before the Reverse Split) ($4.20 as retroactively adjusted to reflect the Merger). The stock options were fully vested at the date of grant. On May 2, 2016, Microbot Israel’s board of directors approved a grant of 33,333 stock options (500,000 stock options before the Reverse Split) (96,482 as retroactively adjusted to reflect the Merger) to certain of its employees and directors. Each stock option was exercisable into an ordinary share, NIS 0.001 par value, of Microbot Israel, at an exercise price equal to the ordinary share’s par value. The stock options were fully vested at the date of grant. As the exercise price of the stock options is nominal, Microbot Israel estimated the fair value of the options as equal to the Company’s share price of $20.25 ($1.35 before the Reverse Split) ($7.05 as retroactively adjusted to reflect the Merger) at the date of grant. On September 12, 2017, the Company adopted the 2017 Equity Incentive Plan (the “Plan”), which Plan authorizes, among other things, the grant of options to purchase shares of common stock to directors, officers and employees of the Company and to other individuals. On September 14, 2017, the board of directors approved a grant of stock options to purchase an aggregate of up to 120,848 shares (1,812,712 shares before the Reverse Split) of common stock to Mr. Harel Gadot, the Company’s Chairman of the Board, President and CEO, at an exercise price per share of $15.75 ($1.05 before the Reverse Split). The stock options vest over a period of 3-5 years as outlined in the option agreements. As a result, the Company recognized compensation expenses for the three months ended September 30, 2019 and 2018 in total amount of $122 and $121 respectively and for the nine months ended September 30, 2019 and 2018 in total amount of $362 and $460 respectively included in general and administrative expenses. On September 14, 2017, the board of directors approved a grant of stock options to purchase an aggregate of up to 72,508 shares (1,087,627 shares before the Reverse Split) of common stock to Mr. Hezi Himelfarb, the Company’s General Manager, COO and a member of the Board, at an exercise price per share of $19.35 ($1.29 before the Reverse Split). The grant was subject to the Israeli Tax Authority’s approval of the plan which occurred on October 14, 2017. In accordance with the option agreement, the options vest for period of 3 years starting from the grand date. As a result, the Company recognized compensation expenses for the three months ended September 30, 2019 and 2018 in the total amount of $108 and $98 respectively and for the nine months ended September 30, 2019 and 2018 in the total amount of $322 and $329 respectively included in research and development. On December 6, 2017, the board of directors approved a grant of 12,698 stock options (190,475 stock options before the Reverse Split) to purchase an aggregate of up to 12,698 shares of common stock to certain of its directors, at an exercise price per share of $15.75 ($1.05 before the Reverse Split). The stock options vest over a period of 3 years as outlined in the option agreements. As a result, the Company recognized compensation expenses for the three months ended September 30, 2019 and 2018 in the total amount of $13 and $14 respectively and for the nine months ended September 30, 2019 and 2018 in the total amount of $40 and $55 respectively included in general and administrative expenses. On December 28, 2017, the board of directors approved a grant of 66,036 stock options (990,543 stock options before the Reverse Split) to purchase an aggregate of up to 66,036 shares of common stock to certain of its employees, at an exercise price per share of $15.3 ($1.02 before the Reverse Split). The stock options vest over a period of 3 years as outlined in the option agreements. As a result, the Company recognized compensation expenses for the three months ended September 30, 2019 and 2018 in the total amount of $37 and $62 respectively and for the nine months ended September 30, 2019 and 2018 in the total amount of $116 and $273 respectively included in research and development expenses. On November 2017, certain employees and consultant exercised 31,453 options (471,794 options before the Reverse Split) to 31,453 ordinary shares at exercise price of 0.001 NIS. In February 2018, an employee exercised options to purchase 2,487 shares (37,300 shares before the Reverse Split) of common stock at an exercise price of $0.001 per share. On August 13, 2018, the board of directors approved a grant of stock options to purchase an aggregate of up to 10,000 shares (150,000 shares before the Reverse Split) of common stock to a non-executive officer, at an exercise price per share of $9 ($0.6 before the Reverse Split). The grant was subject to the Israeli Tax Authority’s approval of the plan which occurred on October 14, 2017. In accordance with the option agreement, the options vest for period of 3 years starting from the grand date. As a result, the Company recognized compensation expenses for the three months ended September 30, 2019 and 2018 in the total amount of $6 and $22 respectively and for the nine months ended September 30, 2019 and 2018 in the total amount of $24 and $22 respectively included in research and development expenses. On January 21, 2019, the board of directors approved a grant of 11,630 stock options to purchase an aggregate of up to 11,630 shares of common stock to certain of its directors, at an exercise price per share of $8.60. The stock options vest over a period of 3 years as outlined in the option agreements As a result, the Company recognized compensation expenses for the three months ended September 30, 2019 and 2018 in the total amount of $7 and $0 respectively and for the nine months ended September 30, 2019 and 2018 in the total amount of $37 and $0 respectively included in general and administrative expenses. On August 12, 2019, the board of directors approved a grant of 17,503 stock options to purchase an aggregate of up to 17,503 shares of common stock to certain of its employees, at an exercise price per share of $5.95. The stock options vest over a period of 3 years as outlined in the option agreements As a result, the Company recognized compensation expenses for the three months ended September 30, 2019 and 2018 in the total amount of $4 and $0 respectively and for the nine months ended September 30, 2019 and 2018 in the total amount of $4 and $0 respectively included in general and administrative expenses. A summary of the Company’s option activity related to options to employees and directors, and related information is as follows: For the Nine Months ended September 30, 2019 Number of stock options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of period 398,308 $ 11.50 $ 108 Granted 29,133 7.00 - Exercised - - - Cancelled - - - Outstanding at end of period 427,441 $ 11.15 $ 417 Vested at end of period 306,723 $ 9.90 $ 417 For the Year ended December 31, 2018 Number of stock options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of period 414,965 $ 11.70 $ 1,859 Granted 10,000 9.00 - Exercised (2,487 ) - - Cancelled (24,170 ) - - Outstanding at end of period 398,308 $ 11.50 $ 108 Vested at end of period 245,010 $ 8.45 $ 108 The aggregate intrinsic value in the table above represents the total intrinsic value, which is calculated as the difference between the fair market value of the common stock and the exercise price, multiplied by the number of in-the-money stock options on those dates that would have been received by the stock option holders had all stock option holders exercised their stock options on those dates as of September 30, 2019 and December 31, 2018 respectively. The stock options outstanding as of September 30, 2019 and December 31, 2018, summarized by exercise prices, are as follows: Exercise price $ Stock options outstanding as of September 30, 2019 Stock options outstanding as of December 31, 2018 Weighted average remaining contractual life – years as of September 30, 2019 Weighted average remaining contractual life – years as of December 31, 2018 Stock options exercisable as of September 30, 2019 Stock options exercisable as of December 31, 2018 4.20 77,846 77,846 6.3 7.0 77,846 77,846 15.75 133,546 133,546 8.0 8.8 83,005 53,752 8.60 11,630 - 9.3 - 4,645 - 9.00 10,000 10,000 9.0 9.8 4,000 - 19.35 72,508 72,508 8.0 8.8 45,318 29,003 5.95 17,503 - 2.8 - - - 15.30 41,866 41,866 8.3 9.0 29,367 21,867 (* ) 62,542 62,542 7.0 7.8 62,542 62,542 427,441 398,308 6.3 7.3 306,723 245,010 (*) Less than $0.01. Compensation expense recorded by the Company for its stock-based employee compensation awards in accordance with ASC 718-10 for the nine months ended September 30, 2019 and 2018 was $906 and $1,139, respectively, and for the three months ended September 30, 2019 and 2018 was $296 and $317, respectively. The fair value of the stock options is estimated at the date of grant using the Black-Scholes options pricing model with the following weighted-average assumptions: Nine Months ended Year ended Expected volatility 133.43%-144.4 % 99.40 % Risk-free interest 1.64 % 2.39 % Dividend yield 0 % 0 % Expected life of up to (years) 6.37-6.73 5.24 Shares issued to service provider On May 24, 2018 the Company issued an aggregate of 6,738 nonrefundable shares (100,000 nonrefundable shares before the Reverse Split) of common stock to CardioSert as part of certain patent acquisition. The Company recorded expenses of approximately $74 with respect to the issuance of these shares included in research and development expenses. Warrants The remaining outstanding warrants and terms as of September 30, 2019 and December 31, 2018 are as follows: Issuance date Outstanding as of December 31, 2018 Outstanding as of September 30, 2019 Exercise Price Exercisable as of September 30, 2019 Exercisable Through Series A (2013) 181 181 $ 2,754.00 181 April 9, 2023 Series A (2015) 676 676 $ 1,377.00 676 April 30, 2020 Series B (2016) (a) 2,741 2,741 $ 40.50 2,741 March 14, 2022 Prior to January 1, 2019, warrants with non-standard anti-dilution provisions (referred to as down round protection) were classified as liabilities and re-measured each reporting period. On January 1, 2019, the Company adopted the provisions of ASU 2017-11, which indicates that a down round feature no longer precludes equity classification when assessing whether an investment is indexed to an entity’s own stock. The Company used a full retrospective approach to adoption and restated its financial statements as of the earliest period presented. The cumulative effect of adoption of ASU 2017-11 resulted in an adjustment to accumulated deficit as of January 1, 2018 of $20 with a corresponding adjustment to additional paid-in capital. Repurchase of Shares The Company had intended to enter into a definitive agreement with up to three Israeli shareholders, some of whom are directors of the Company, that were former shareholders of Microbot Israel, pursuant to which the Company would repurchase, at a discount on the fair value of the share at the date of repurchase, up to $500 of common stock held by them, in the aggregate, if and to the extent such shareholders are unable to sell enough of their shares to cover certain of their Israeli tax liabilities resulting from the Merger. Such repurchase(s), if any, would occur only after the two-year anniversary of the Merger. The transaction would have been subject to negotiating final terms and entering into definitive agreements with such shareholders. The Company evaluated whether an embedded derivative that requires bifurcation exists within such shares that may be subject to repurchase. The Company concluded the fair value of such derivative instrument would be nominal and, in any case, would represent an asset to the Company as (a) the settlement requires acquiring the shares at a discount on the fair market value of the share at the time of re purchase and in no circumstances the acquisition price will be higher than approximately one dollar per share (representing 25% discount on the fair market value of the share at the merger closing date) and (b) it is assumed that the selling shareholders would use such right as last resort as such repurchase at a discount on the fair market value of such shares results in a loss to be incurred by the selling shareholders. In accordance with ASC 480-10-S99-3A (formerly EITF D-98), the Company classified the maximum amount it may be required to pay in the event the repurchase right is exercised ($500) as temporary equity. As of December 31, 2018, the Company determined that no obligation remained to enter into any such definitive agreement as the two-year anniversary of the Merger was in November 2018 and therefore there was no liability for the Company to repurchase any shares from the three Israeli shareholders. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Sep. 30, 2019 | |
Subsequent Events [Abstract] | |
Subsequent Events | NOTE 7 - SUBSEQUENT EVENTS On October 23, 2019, the board of directors approved a grant of options to purchase an aggregate of up to 19,760 shares of common stock to the Company’s non-management directors, at an exercise price per share of $5.06. The stock options vest over a period of 3 years as outlined in the option agreements. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2019 | |
Accounting Policies [Abstract] | |
Unaudited Interim Financial Statements | Unaudited Interim Financial Statements: The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission (“SEC”) regulations. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). Operating results for the three- and nine-month periods ended September 30, 2019, are not necessarily indicative of the results that may be expected for the year ended December 31, 2019. |
Significant Accounting Policies | Significant Accounting Policies: The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual audited financial statements with the exception of the following: |
Short-term Investments | Short-term Investments: The Company began investing excess cash in short-term investments during the first quarter of 2019. Marketable debt securities are considered to be available for sale and are carried at fair value. Unrealized gains and losses net of tax, if any, are reported as a separate component of shareholders’ equity. The cost of marketable debt securities classified as available for sale is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Realized gains and losses and declines in value judged to be other than temporary, if any, are also included in other income, net. Interest on securities classified as available for sale is included in interest income. The cost of securities sold is based on the specific identification method. Management evaluates whether available-for-sale securities are other-than-temporarily impaired (OTTI) on a quarterly basis. Debt securities with unrealized losses are considered OTTI if the Company intends to sell the security or if it is more likely than not that the Company will be required to sell such security prior to any anticipated recovery. If management determines that a security is OTTI under these circumstances, the impairment recognized in earnings is measured as the entire difference between the amortized cost and the then-current fair value. During the three and nine-months ended September 30, 2019, no investment OTTI losses were realized. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments: The carrying values of cash and cash equivalents, other receivable and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. The Company measures the fair value of certain of its financial instruments (marketable debt security) on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 Level 2 Level 3 |
Reclassifications | Reclassifications: |
Leases | Leases: In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842). This ASU requires entities that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than 12 months. The Company adopted this ASU effective January 1, 2019 using the modified retrospective application, applying the new standard to leases in place as of the adoption date. Prior periods have not been adjusted. Arrangements that are determined to be leases at inception are recognized as long-term right-of-use assets (“ROU”) and lease liabilities in the condensed consolidated balance sheet at lease commencement. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future fixed lease payments over the lease term at commencement date. As most of the Company’s leases do not provide an implicit rate, the Company applies its incremental borrowing rate based on the economic environment at commencement date in determining the present value of future payments. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases or payments are recognized on a straight-line basis over the lease term. |
Warrants | Warrants: Prior to January 1, 2019, warrants with non-standard anti-dilution provisions (referred to as down round protection) were classified as liabilities and re-measured each reporting period. On January 1, 2019, the Company adopted the provisions of Accounting Standards Update (“ASU”) 2017-11, which includes Part I “Accounting for Certain Financial Instruments with Down Round Features” and Part II “Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-Controlling Interests with a Scope Exception”, which indicates that a down round feature no longer precludes equity classification when assessing whether an investment is indexed to an entity’s own stock. The Company used a full retrospective approach to adoption and restated its financial statements as of the earliest period presented. As a result of the adoption of ASU 2017-11, the Company’s warrants were reclassified from liabilities to shareholders’ equity. The cumulative effect of adoption of ASU 2017-11 resulted as follows: For the For the Derivative warrant liability $ (5 ) $ (8) Additional paid-in capital $ 3 $ 28 Accumulated deficit $ 2 $ 20 Refer to Note 6 for further information regarding the outstanding warrants as of September 30, 2019. |
Recent Accounting Standards | Recent Accounting Standards: In June 2016, the FASB issued ASU 2016-13 “Financial Instruments – Credit Losses” to improve information on credit losses for financial assets and net investment in leases that are not accounted for at fair value through net income. This ASU replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses. This ASU is effective for the Company in the first quarter of 2020, with early adoption permitted. The Company does not expect that this ASU will have a material effect on the Company’s consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements”, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. This ASU removes, modifies, and adds certain disclosure requirements, and is effective for the Company beginning on January 1, 2020. The Company does not expect that this ASU will have a material effect on the Company’s consolidated financial statements. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Accounting Policies [Abstract] | |
Schedule of Cumulative Effect of Adoption of ASU 2017-11 | The cumulative effect of adoption of ASU 2017-11 resulted as follows: For the For the Derivative warrant liability $ (5 ) $ (8) Additional paid-in capital $ 3 $ 28 Accumulated deficit $ 2 $ 20 |
Short-Term Investments (Tables)
Short-Term Investments (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Short-term Investments [Abstract] | |
Schedule of Marketable Debt Securities | The following table summarizes the Company’s marketable debt securities as of September 30, 2019 and December 31, 2018. As of September 30, 2019 Amortized cost Unrealized gains Realized gains Fair value US Treasury Bond $ 2,503 $ - $ - $ 2,503 As of December 31, 2018 Amortized Cost Unrealized gains Realized gains Fair value US Treasury Bond $ - $ - $ - $ - |
Leases (Tables)
Leases (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Leases [Abstract] | |
Schedule of Supplemental Cash Flow Information Related to Operating Leases | Supplemental cash flow information related to operating leases was as follows (unaudited): Nine Months ended September 30, 2019 Cash payments for operating leases $ 235 |
Schedule of Supplemental Information Related to Leases | Leases recorded on the balance sheet consist of the following (in thousands): September 30, 2019 Assets Operating lease right of use asset $ 421 Liabilities Operating lease – current $ 314 Operating lease - non-current $ 131 $ 445 September 30, 2019 Operating leases weighted average remaining lease term (in years) 2 Operating leases weighted average discount rate 7 % |
Schedule of Maturities of Lease Liabilities | Undiscounted maturities of operating lease payments as of September 30, 2019 are summarized as follows (in thousands): Operating Leases Remainder of 2019 $ 83 2020 302 2021 79 Total future lease payments $ 464 Less imputed interest (19 ) Total lease liability balance $ 445 |
Share Capital (Tables)
Share Capital (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Equity [Abstract] | |
Summary of Stock Option Activity | A summary of the Company’s option activity related to options to employees and directors, and related information is as follows: For the Nine months ended September 30, 2019 Number of stock options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of period 398,308 $ 11.50 $ 108 Granted 29,133 7.00 - Exercised - - - Cancelled - - - Outstanding at end of period 427,441 $ 11.15 $ 417 Vested at end of period 306,723 $ 9.90 $ 417 For the Year ended December 31, 2018 Number of stock options Weighted average exercise price Aggregate intrinsic value Outstanding at beginning of period 414,965 $ 11.70 $ 1,859 Granted 10,000 9.00 - Exercised (2,487 ) - - Cancelled (24,170 ) - - Outstanding at end of period 398,308 $ 11.50 $ 108 Vested at end of period 245,010 $ 8.45 $ 108 |
Schedule of Stock Options Outstanding | The stock options outstanding as of September 30, 2019 and December 31, 2018, summarized by exercise prices, are as follows: Exercise price $ Stock options outstanding as of September 30, 2019 Stock options outstanding as of December 31, 2018 Weighted average remaining contractual life – years as of September 30, 2019 Weighted average remaining contractual life – years as of December 31, 2018 Stock options exercisable as of September 30, 2019 Stock options exercisable as of December 31, 2018 4.20 77,846 77,846 6.3 7.0 77,846 77,846 15.75 133,546 133,546 8.0 8.8 83,005 53,752 8.60 11,630 - 9.3 - 4,645 - 9.00 10,000 10,000 9.0 9.8 4,000 - 19.35 72,508 72,508 8.0 8.8 45,318 29,003 5.95 17,503 - 2.8 - - - 15.30 41,866 41,866 8.3 9.0 29,367 21,867 (* ) 62,542 62,542 7.0 7.8 62,542 62,542 427,441 398,308 6.3 7.3 306,723 245,010 (*) Less than $0.01. |
Schedule of Stock Options Valuation Assumptions | The fair value of the stock options is estimated at the date of grant using the Black-Scholes options pricing model with the following weighted-average assumptions: Nine Months ended Year ended Expected volatility 133.43%-144.4 % 99.40 % Risk-free interest 1.64 % 2.39 % Dividend yield 0 % 0 % Expected life of up to (years) 6.37-6.73 5.24 |
Schedule of Warrants Outstanding | The remaining outstanding warrants and terms as of September 30, 2019 and December 31, 2018 are as follows: Issuance date Outstanding as of December 31, 2018 Outstanding as of September 30, 2019 Exercise Price Exercisable as of September 30, 2019 Exercisable Through Series A (2013) 181 181 $ 2,754.00 181 April 9, 2023 Series A (2015) 676 676 $ 1,377.00 676 April 30, 2020 Series B (2016) (a) 2,741 2,741 $ 40.50 2,741 March 14, 2022 |
General (Details Narrative)
General (Details Narrative) - USD ($) $ in Thousands | Sep. 04, 2018 | Sep. 30, 2019 | Dec. 31, 2018 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||
Accumulated deficit | $ (33,241) | $ (27,864) | |
Reverse stock split | 1:15 reverse stock split | ||
Reverse stock split, shares | 15 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Schedule of Cumulative Effect of Adoption of ASU 2017-11 (Details) - USD ($) $ in Thousands | Jan. 02, 2019 | Dec. 31, 2018 | Sep. 30, 2018 |
Derivative Warrant Liability [Member] | Accounting Standards Update 2017-11 [Member] | |||
Cumulative effect adjustment | $ (8) | $ (5) | |
Additional Paid-In Capital [Member] | Accounting Standards Update 2017-11 [Member] | |||
Cumulative effect adjustment | 28 | 3 | |
Accumulated Deficit [Member] | |||
Cumulative effect adjustment | $ 20 | ||
Accumulated Deficit [Member] | Accounting Standards Update 2017-11 [Member] | |||
Cumulative effect adjustment | $ 20 | $ 2 |
Short-Term Investments - Schedu
Short-Term Investments - Schedule of Marketable Debt Securities (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2019 | Dec. 31, 2018 | ||
Unrealized gains | ||||
US Treasury Bond [Member] | ||||
Amortized cost | 2,503 | |||
Unrealized gains | [1] | |||
Realized gains | ||||
Fair value | $ 2,503 | |||
[1] | Less than 1 |
Leases (Details Narrative)
Leases (Details Narrative) - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 |
Leases [Abstract] | ||
Operating right-of-use assets | $ 421 | |
Lease liabilities for operating leases | $ 445 |
Leases - Schedule of Supplement
Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details) $ in Thousands | 9 Months Ended |
Sep. 30, 2019USD ($) | |
Leases [Abstract] | |
Cash payments for operating leases | $ 235 |
Leases - Schedule of Suppleme_2
Leases - Schedule of Supplemental Information Related to Leases (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 |
Leases [Abstract] | ||
Operating lease right of use asset | $ 421 | |
Operating lease - current | 314 | |
Operating lease - non-current | 131 | |
Total Operating lease liability | $ 445 | |
Weighted Average Terms Operating leases | 2 years | |
Weighted Average Discount Rate Operating leases | 7.00% |
Leases - Schedule of Maturities
Leases - Schedule of Maturities of Lease Liabilities (Details) $ in Thousands | Sep. 30, 2019USD ($) |
Leases [Abstract] | |
Remainder of 2019 | $ 83 |
2020 | 302 |
2021 | 79 |
Total future lease payments | 464 |
Less imputed interest | (19) |
Total lease liability balance | $ 445 |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) | Apr. 28, 2019USD ($) | Mar. 26, 2019USD ($) | Feb. 28, 2019USD ($) | May 24, 2018shares | Apr. 10, 2018USD ($)shares | Jan. 04, 2018USD ($)$ / shares | Jan. 04, 2018ILS (₪) | Jun. 08, 2017USD ($) | Sep. 30, 2018USD ($) | Jul. 31, 2018USD ($) | Apr. 30, 2018USD ($) | Jun. 30, 2012 | Sep. 30, 2019USD ($) |
Purchase Price of Plaintiffs | $ 3,375,000 | ||||||||||||
Monthly Consultation Fee | ₪ | ₪ 40,000 | ||||||||||||
Alliance Investment Management, Ltd. [Member] | |||||||||||||
Litigation settlement | $ 480,000 | ||||||||||||
CardioSert Ltd [Member] | |||||||||||||
Initial Payment | $ 250,000 | $ 50,000 | |||||||||||
Number of Common Shares Acquired | shares | 6,738 | 6,738 | |||||||||||
Number of Common Shares Acquired, Value | $ 74,000 | ||||||||||||
Buy Back Amount Per Patent | $ / shares | $ 1 | ||||||||||||
CardioSert Ltd [Member] | Before Reverse Split [Member] | |||||||||||||
Number of Common Shares Acquired | shares | 100,000 | 100,000 | |||||||||||
Bonding Agent [Member] | |||||||||||||
Purchase Price of Plaintiffs | $ 4,200,000 | ||||||||||||
Additional Expenses Respect to Interest from the Judgement Date | $ 178,000 | ||||||||||||
Securities Purchase Agreement [Member] | |||||||||||||
Purchase Price of Plaintiffs | $ 3,375,000 | ||||||||||||
Loss Contingency, Damages Sought | $ 1,000,000 | ||||||||||||
Minimum [Member] | Alliance Investment Management, Ltd. [Member] | |||||||||||||
Beneficial Ownership Percentage | 10.00% | ||||||||||||
Minimum [Member] | CardioSert Ltd [Member] | |||||||||||||
Investments | $ 2,000,000 | ||||||||||||
Minimum [Member] | Technion Research and Development Foundation Limited [Member] | |||||||||||||
Royalties Payable as Percentage of Future Sales | 1.50% | ||||||||||||
Maximum [Member] | Technion Research and Development Foundation Limited [Member] | |||||||||||||
Royalties Payable as Percentage of Future Sales | 3.00% | ||||||||||||
Second Phase [Member] | Contract Research Agreements [Member] | |||||||||||||
Contract Expected Costs | $ 248,000 | $ 130,000 | |||||||||||
Phase 2.1 [Member] | Contract Research Agreements [Member] | |||||||||||||
Contract Expected Costs | $ 213,000 | ||||||||||||
Israeli Innovation Authority [Member] | 2013 Through September 30, 2019 [Member] | |||||||||||||
Total Grants Obtained | $ 1,500,000 | ||||||||||||
Israeli Innovation Authority [Member] | 2013 Through September 30, 2019 [Member] | Minimum [Member] | |||||||||||||
Royalties Payable as Percentage of Future Sales | 3.00% | ||||||||||||
Israeli Innovation Authority [Member] | 2013 Through September 30, 2019 [Member] | Maximum [Member] | |||||||||||||
Royalties Payable as Percentage of Future Sales | 3.50% |
Share Capital (Details Narrativ
Share Capital (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands | Aug. 12, 2019 | Jan. 23, 2019 | Jan. 21, 2019 | Jan. 15, 2019 | Jan. 14, 2019 | Aug. 13, 2018 | May 24, 2018 | Apr. 10, 2018 | Dec. 28, 2017 | Dec. 06, 2017 | Sep. 14, 2017 | Jun. 05, 2017 | Jan. 05, 2017 | Dec. 27, 2016 | May 02, 2016 | Feb. 28, 2018 | Nov. 30, 2017 | Sep. 30, 2014 | Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 | Sep. 10, 2019 | Jan. 02, 2019 | |
Authorized capital stock | 61,000,000 | 61,000,000 | 221,000,000 | |||||||||||||||||||||||
Common stock, shares authorized | 60,000,000 | 60,000,000 | 60,000,000 | 220,000,000 | ||||||||||||||||||||||
Common stock, shares issued | 4,307,666 | 4,307,666 | 3,012,343 | |||||||||||||||||||||||
Common stock, shares outstanding | 4,307,666 | 4,307,666 | 3,012,343 | |||||||||||||||||||||||
Proceeds from issuance of shares | $ 9,562 | |||||||||||||||||||||||||
Number of stock options granted | 29,133 | 10,000 | ||||||||||||||||||||||||
Weighted-average exercise price per share, granted | $ 7 | $ 9 | ||||||||||||||||||||||||
Ordinary shares, par value | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||||||||
Stock-based employee compensation | $ 296 | $ 317 | $ 906 | 1,139 | ||||||||||||||||||||||
Number of option exercised | 2,487 | |||||||||||||||||||||||||
Repurchase of common stock | $ 500 | |||||||||||||||||||||||||
Fair market value percentage | 25.00% | 25.00% | ||||||||||||||||||||||||
Temporary equity value | $ 500 | |||||||||||||||||||||||||
Accumulated Deficit [Member] | ||||||||||||||||||||||||||
Cumulative effect adjustment | $ 20 | |||||||||||||||||||||||||
Purchaser [Member] | ||||||||||||||||||||||||||
Number of common stock shares sold during the period | 47,163 | |||||||||||||||||||||||||
Common stock price per share | $ 74 | |||||||||||||||||||||||||
Proceeds from issuance of shares | $ 3,500 | |||||||||||||||||||||||||
Placement agent fee and expenses | $ 210 | |||||||||||||||||||||||||
Investor [Member] | ||||||||||||||||||||||||||
Number of common stock shares sold during the period | 252,652 | |||||||||||||||||||||||||
Common stock price per share | $ 40.50 | |||||||||||||||||||||||||
Proceeds from issuance of shares | $ 10,125 | |||||||||||||||||||||||||
Placement agent fee and expenses | $ 922 | |||||||||||||||||||||||||
Investor [Member] | Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||
Number of common stock shares sold during the period | 250,000 | 590,000 | 330,000 | |||||||||||||||||||||||
Common stock price per share | $ 9.875 | $ 10 | $ 6.50 | |||||||||||||||||||||||
Proceeds from issuance and sale of stock | $ 2,470 | $ 5,900 | ||||||||||||||||||||||||
Board of Directors [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 11,630 | 12,698 | ||||||||||||||||||||||||
Weighted-average exercise price per share, granted | $ 8.60 | $ 15.75 | ||||||||||||||||||||||||
Stock option vested term | 3 years | 3 years | ||||||||||||||||||||||||
Board of Directors [Member] | General and Administrative Expense [Member] | ||||||||||||||||||||||||||
Stock-based employee compensation | $ 13 | 14 | 40 | 55 | ||||||||||||||||||||||
Board of Directors [Member] | NIS [Member] | ||||||||||||||||||||||||||
Ordinary shares, par value | $ 0.001 | |||||||||||||||||||||||||
Harel Gadot [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 120,848 | |||||||||||||||||||||||||
Weighted-average exercise price per share, granted | $ 15.75 | |||||||||||||||||||||||||
Harel Gadot [Member] | General and Administrative Expense [Member] | ||||||||||||||||||||||||||
Stock-based employee compensation | 122 | 121 | 362 | 460 | ||||||||||||||||||||||
Harel Gadot [Member] | Minimum [Member] | ||||||||||||||||||||||||||
Stock option vested term | 3 years | |||||||||||||||||||||||||
Harel Gadot [Member] | Maximum [Member] | ||||||||||||||||||||||||||
Stock option vested term | 5 years | |||||||||||||||||||||||||
Hezi Himelfarb [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 72,508 | |||||||||||||||||||||||||
Weighted-average exercise price per share, granted | $ 19.35 | |||||||||||||||||||||||||
Stock option vested term | 3 years | |||||||||||||||||||||||||
Hezi Himelfarb [Member] | Research and Development Expense [Member] | ||||||||||||||||||||||||||
Stock-based employee compensation | 108 | 98 | 322 | 329 | ||||||||||||||||||||||
Employees [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 17,503 | 66,036 | ||||||||||||||||||||||||
Weighted-average exercise price per share, granted | $ 5.95 | $ 15.3 | ||||||||||||||||||||||||
Ordinary shares, par value | $ 0.001 | |||||||||||||||||||||||||
Stock option vested term | 3 years | 3 years | ||||||||||||||||||||||||
Stock-based employee compensation | 4 | 0 | 4 | 0 | ||||||||||||||||||||||
Number of option exercised | 2,487 | |||||||||||||||||||||||||
Employees [Member] | Research and Development Expense [Member] | ||||||||||||||||||||||||||
Stock-based employee compensation | 37 | 62 | 116 | 273 | ||||||||||||||||||||||
Employees and Consultant [Member] | ||||||||||||||||||||||||||
Number of option exercised | 31,453 | |||||||||||||||||||||||||
Employees and Consultant [Member] | NIS [Member] | ||||||||||||||||||||||||||
Ordinary shares, par value | $ 0.001 | |||||||||||||||||||||||||
Non-Executive Officer [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 10,000 | |||||||||||||||||||||||||
Weighted-average exercise price per share, granted | $ 9 | |||||||||||||||||||||||||
Stock option vested term | 3 years | |||||||||||||||||||||||||
Non-Executive Officer [Member] | Research and Development Expense [Member] | ||||||||||||||||||||||||||
Stock-based employee compensation | 6 | 22 | 24 | 22 | ||||||||||||||||||||||
Board of Directors [Member] | ||||||||||||||||||||||||||
Stock-based employee compensation | $ 7 | $ 0 | $ 37 | $ 0 | ||||||||||||||||||||||
Microbot Israel [Member] | Board of Directors [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 33,333 | 26,906 | ||||||||||||||||||||||||
Number of stock option granted as adjusted to reflect merger | 96,482 | 77,846 | ||||||||||||||||||||||||
Weighted-average exercise price per share, granted | $ 20.25 | $ 12 | ||||||||||||||||||||||||
Stock option merger retroactively adjusted exercise price per share | $ 7.05 | $ 4.20 | ||||||||||||||||||||||||
CardioSert Ltd [Member] | ||||||||||||||||||||||||||
Number of common shares acquired | 6,738 | 6,738 | ||||||||||||||||||||||||
CardioSert Ltd [Member] | Research and Development Expense [Member] | ||||||||||||||||||||||||||
Acquisition price of assets | $ 74 | |||||||||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||||||||
Rights to acquire shares of common stock | 655,962 | |||||||||||||||||||||||||
Number of option exercised | [1] | 2,487 | ||||||||||||||||||||||||
Common Stock [Member] | Board of Directors [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 11,630 | |||||||||||||||||||||||||
Common Stock [Member] | Directors [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 12,698 | |||||||||||||||||||||||||
Common Stock [Member] | Employees [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 17,503 | 66,036 | ||||||||||||||||||||||||
Before Reverse Split [Member] | Purchaser [Member] | ||||||||||||||||||||||||||
Number of common stock shares sold during the period | 700,000 | |||||||||||||||||||||||||
Common stock price per share | $ 5 | |||||||||||||||||||||||||
Before Reverse Split [Member] | Investor [Member] | ||||||||||||||||||||||||||
Number of common stock shares sold during the period | 3,750,000 | |||||||||||||||||||||||||
Common stock price per share | $ 2.70 | |||||||||||||||||||||||||
Before Reverse Split [Member] | Board of Directors [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 190,475 | |||||||||||||||||||||||||
Weighted-average exercise price per share, granted | $ 1.05 | |||||||||||||||||||||||||
Before Reverse Split [Member] | Harel Gadot [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 1,812,712 | |||||||||||||||||||||||||
Weighted-average exercise price per share, granted | $ 1.05 | |||||||||||||||||||||||||
Before Reverse Split [Member] | Hezi Himelfarb [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 1,087,627 | |||||||||||||||||||||||||
Weighted-average exercise price per share, granted | $ 1.29 | |||||||||||||||||||||||||
Before Reverse Split [Member] | Employees [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 990,543 | |||||||||||||||||||||||||
Weighted-average exercise price per share, granted | $ 1.02 | |||||||||||||||||||||||||
Number of option exercised | 37,300 | |||||||||||||||||||||||||
Before Reverse Split [Member] | Employees and Consultant [Member] | ||||||||||||||||||||||||||
Number of option exercised | 471,794 | |||||||||||||||||||||||||
Before Reverse Split [Member] | Non-Executive Officer [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 150,000 | |||||||||||||||||||||||||
Weighted-average exercise price per share, granted | $ 0.6 | |||||||||||||||||||||||||
Before Reverse Split [Member] | Microbot Israel [Member] | Board of Directors [Member] | ||||||||||||||||||||||||||
Number of stock options granted | 500,000 | 403,592 | ||||||||||||||||||||||||
Weighted-average exercise price per share, granted | $ 1.35 | $ 0.80 | ||||||||||||||||||||||||
Before Reverse Split [Member] | CardioSert Ltd [Member] | ||||||||||||||||||||||||||
Number of common shares acquired | 100,000 | 100,000 | ||||||||||||||||||||||||
Pre-Funded Warrant [Member] | Investor [Member] | Securities Purchase Agreement [Member] | ||||||||||||||||||||||||||
Warrant to purchase for common stock | 125,323 | |||||||||||||||||||||||||
Warrant price per share | $ 6.49 | |||||||||||||||||||||||||
Proceeds from issuance and sale of stock | $ 3,000 | |||||||||||||||||||||||||
Common Stock [Member] | Before Reverse Split [Member] | ||||||||||||||||||||||||||
Rights to acquire shares of common stock | 9,735,925 | |||||||||||||||||||||||||
Series A Convertible Preferred Stock [Member] | ||||||||||||||||||||||||||
Designated preferred stock | 9,736 | |||||||||||||||||||||||||
[1] | Share data as of December 31, 2017, June 30, 2018, and for the periods then ended represent the number of shares adjusted to retroactively reflect the 1:15 reverse stock split effected on September 4, 2018. Refer to Note 1 for further information. |
Share Capital - Summary of Stoc
Share Capital - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 9 Months Ended | 12 Months Ended |
Sep. 30, 2019 | Dec. 31, 2018 | |
Equity [Abstract] | ||
Number of stock options outstanding, Outstanding at beginning of period | 398,308 | 414,965 |
Number of stock options outstanding, Granted | 29,133 | 10,000 |
Number of stock options outstanding, Exercised | (2,487) | |
Number of stock options outstanding, Cancelled | (24,170) | |
Number of stock options outstanding, Outstanding at end of period | 427,441 | 398,308 |
Number of stock options outstanding, Vested at end of period | 306,723 | 245,010 |
Weighted average exercise price, Outstanding at beginning of period | $ 11.50 | $ 11.70 |
Weighted average exercise price, Granted | 7 | 9 |
Weighted average exercise price, Exercised | ||
Weighted average exercise price, Cancelled | ||
Weighted average exercise price, Outstanding at end of period | 11.15 | 11.50 |
Weighted average exercise price, Vested at end of period | $ 9.90 | $ 8.45 |
Aggregate intrinsic value, Stock Options Outstanding at beginning of period | $ 108 | $ 1,859 |
Aggregate intrinsic value, Stock Options Outstanding at end of period | 417 | 108 |
Aggregate intrinsic value, Vested at end of period | $ 417 | $ 108 |
Share Capital - Schedule of Sto
Share Capital - Schedule of Stock Options Outstanding (Details) - $ / shares | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2019 | Dec. 31, 2018 | ||
Stock options outstanding | 427,441 | 398,308 | |
Weighted average remaining contractual life | 6 years 3 months 19 days | 7 years 3 months 19 days | |
Stock options exercisable | 306,723 | 245,010 | |
Exercise Price One [Member] | |||
Exercise price | $ 4.20 | $ 4.20 | |
Stock options outstanding | 77,846 | 77,846 | |
Weighted average remaining contractual life | 6 years 3 months 19 days | 7 years | |
Stock options exercisable | 77,846 | 77,846 | |
Exercise Price Two [Member] | |||
Exercise price | $ 15.75 | $ 15.75 | |
Stock options outstanding | 133,546 | 133,546 | |
Weighted average remaining contractual life | 8 years | 8 years 9 months 18 days | |
Stock options exercisable | 83,005 | 53,752 | |
Exercise Price Three [Member] | |||
Exercise price | $ 8.60 | $ 8.60 | |
Stock options outstanding | 11,630 | ||
Weighted average remaining contractual life | 9 years 3 months 19 days | 0 years | |
Stock options exercisable | 4,645 | ||
Exercise Price Four [Member] | |||
Exercise price | $ 9 | $ 9 | |
Stock options outstanding | 10,000 | 10,000 | |
Weighted average remaining contractual life | 9 years | 9 years 9 months 18 days | |
Stock options exercisable | 4,000 | ||
Exercise Price Five [Member] | |||
Exercise price | $ 19.35 | $ 19.35 | |
Stock options outstanding | 72,508 | 72,508 | |
Weighted average remaining contractual life | 8 years | 8 years 9 months 18 days | |
Stock options exercisable | 45,318 | 29,003 | |
Exercise Price Six [Member] | |||
Exercise price | $ 5.95 | $ 5.95 | |
Stock options outstanding | 17,503 | ||
Weighted average remaining contractual life | 2 years 9 months 18 days | 0 years | |
Stock options exercisable | |||
Exercise Price Seven [Member] | |||
Exercise price | $ 15.30 | $ 15.30 | |
Stock options outstanding | 41,866 | 41,866 | |
Weighted average remaining contractual life | 8 years 3 months 19 days | 9 years | |
Stock options exercisable | 29,367 | 21,867 | |
Exercise Price Eight [Member] | |||
Exercise price | [1] | ||
Stock options outstanding | 62,542 | 62,542 | |
Weighted average remaining contractual life | 7 years | 7 years 9 months 18 days | |
Stock options exercisable | 62,542 | 62,542 | |
[1] | Less than $0.01. |
Share Capital - Schedule of S_2
Share Capital - Schedule of Stock Options Valuation Assumptions (Details) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2019 | Dec. 31, 2018 | |
Expected volatility, minimum | 133.43% | |
Expected volatility, maximum | 144.40% | |
Expected volatility | 99.40% | |
Risk-free interest | 1.64% | 2.39% |
Dividend yield | 0.00% | 0.00% |
Expected life of up to (years) | 5 years 2 months 27 days | |
Minimum [Member] | ||
Expected life of up to (years) | 6 years 4 months 13 days | |
Maximum [Member] | ||
Expected life of up to (years) | 6 years 8 months 23 days |
Share Capital - Schedule of War
Share Capital - Schedule of Warrants Outstanding (Details) - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2019 | Dec. 31, 2018 | |
Series A (2013) [Member] | ||
Number of outstanding warrants | 181 | 181 |
Exercise price | $ 2,754 | $ 2,754 |
Number of exercisable warrants | 181 | |
Exercisable Through | April 9, 2023 | April 9, 2023 |
Series A (2015) [Member] | ||
Number of outstanding warrants | 676 | 676 |
Exercise price | $ 1,377 | $ 1,377 |
Number of exercisable warrants | 676 | |
Exercisable Through | April 30, 2020 | April 30, 2020 |
Series B (2016) [Member] | ||
Number of outstanding warrants | 2,741 | 2,741 |
Exercise price | $ 40.50 | $ 40.50 |
Number of exercisable warrants | 2,741 | |
Exercisable Through | March 14, 2022 | March 14, 2022 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - $ / shares | Oct. 23, 2019 | Sep. 30, 2019 | Dec. 31, 2018 |
Number of stock options granted | 29,133 | 10,000 | |
Exercise price per share | $ 7 | $ 9 | |
Non-management Directors [Member] | Subsequent Event [Member] | Option Agreements [Member] | |||
Number of stock options granted | 19,760 | ||
Exercise price per share | $ 5.06 | ||
Stock options vesting | 3 years |